NewsRSS3 days ago
A patient shares their experience moving from pediatric (children's) doctors to adult healthcare providers. The article describes the mixed feelings of relief and worry that come with this major life transition, using a waiting room scene to explore how gratitude and fear can happen at the same time.
WHY IT MATTERSTransitioning from pediatric to adult care is a critical moment for patients with rare diseases like SMA, where continuity of specialized treatment and emotional support can directly affect health outcomes and quality of life.
Clinical trialCLINICALTRIALSApr 14
Researchers are testing a new medicine called pozelimab in young children ages 1 to 5 who have CHAPLE disease, a rare inherited condition that affects the stomach, intestines, heart, and blood vessels. This study is checking whether the medicine is safe and well-tolerated in this young age group. CHAPLE disease can cause serious symptoms, so finding safe treatments for young children is important.
WHY IT MATTERSThis is the first safety trial of pozelimab in very young children (ages 1-5) with CHAPLE disease, offering families of affected toddlers a potential treatment option when few alternatives exist for this life-threatening condition.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called pacritinib in people ages 12 and older who have myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms — rare blood disorders where the bone marrow doesn't make enough healthy blood cells. The drug works by blocking several proteins that may be causing these diseases. This is an early-stage study sponsored by the National Cancer Institute that will start recruiting patients in April 2026.
WHY IT MATTERSThis trial offers patients with myelodysplastic syndromes access to a novel multi-targeted kinase inhibitor that may address disease mechanisms not covered by current standard treatments, with enrollment beginning in April 2026.
Clinical trialUNITERAREApr 3
Researchers are testing a new technology called 'digital twins' to help prevent second strokes in patients with three rare brain conditions: moyamoya disease, cerebral amyloid angiopathy, and previous stroke history. A digital twin is a computer model of a patient's brain that doctors can use to predict what treatments might work best for that individual. This study will randomly assign patients to either receive care guided by this digital twin technology or standard care, and compare which approach prevents more strokes.
WHY IT MATTERSThis trial offers patients with moyamoya disease or cerebral amyloid angiopathy who have had a stroke access to personalized, AI-guided prevention strategies that could reduce their risk of future strokes.
ResearchPUBMEDApr 1
Doctors are getting better at using a special imaging machine called PET/MR that combines two types of scans to diagnose rare diseases in children. This machine is especially helpful because it takes clearer pictures while using less radiation than older machines, which is important for kids. The machine works well for finding tumors, genetic disorders, and inflammatory diseases, and doctors can use it to check how well treatments are working.
WHY IT MATTERSIf your child has a rare disease requiring imaging, PET/MR technology may reduce their radiation exposure and the number of separate scans needed compared to traditional imaging methods.
ResearchPUBMEDApr 1
Scientists are developing a new technology called Digital Twins—computer models that act like virtual copies of individual patients. These virtual copies could help doctors diagnose rare childhood diseases faster and find better treatments by testing ideas on the computer before trying them on real patients. This is especially helpful for rare diseases because there aren't many patients to study, and it's hard to do traditional research on children.
WHY IT MATTERSDigital twins could speed up diagnosis and enable personalized treatment plans for children with rare diseases, potentially reducing the years of diagnostic delay that currently affects most pediatric rare disease patients.
ResearchPUBMEDApr 1
Researchers in Italy tested a new way to diagnose rare genetic diseases in children using whole genome sequencing—a test that reads all of a person's genetic code. Between 2018 and 2022, they studied 64 children with complex neurological problems that doctors couldn't figure out. This study shows whether this genetic test could help find answers faster for kids with mysterious rare diseases.
WHY IT MATTERSIf your child has unexplained neurological symptoms and multiple doctors haven't found a diagnosis, this research demonstrates that whole genome sequencing through healthcare systems may finally provide answers—potentially ending years of diagnostic uncertainty.
ResearchPUBMEDMar 26
Doctors who treat children with rare lung diseases in German-speaking countries were surveyed about their experience and confidence in diagnosing and treating these conditions. The study found that while common rare lung diseases like cystic fibrosis have good support systems, many other rare lung diseases don't have clear treatment guidelines. Researchers want to understand what training and resources doctors need to better help children with these uncommon lung problems.
WHY IT MATTERSIf you have a child with a rare lung disease, this research could lead to better training for pediatric lung doctors in your region, potentially reducing diagnostic delays and improving access to specialized care.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
WHY IT MATTERSThis trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.